1. Prendergast, George C, Metz, Richard, Muller, Alexander J, Merlo, Lauren M F, Mandik-Nayak, Laura. 2014. IDO2 in Immunomodulation and Autoimmune Disease. In Frontiers in immunology, 5, 585. doi:10.3389/fimmu.2014.00585. https://pubmed.ncbi.nlm.nih.gov/25477879/
2. Nevler, Avinoam, Muller, Alexander J, Sutanto-Ward, Erika, Prendergast, George C, Brody, Jonathan R. 2018. Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers. In Clinical cancer research : an official journal of the American Association for Cancer Research, 25, 724-734. doi:10.1158/1078-0432.CCR-18-0814. https://pubmed.ncbi.nlm.nih.gov/30266763/
3. Mondanelli, Giada, Mandarano, Martina, Belladonna, Maria Laura, Grohmann, Ursula, Volpi, Claudia. 2021. Current Challenges for IDO2 as Target in Cancer Immunotherapy. In Frontiers in immunology, 12, 679953. doi:10.3389/fimmu.2021.679953. https://pubmed.ncbi.nlm.nih.gov/33968089/
4. Kado, Sarah Y, Bein, Keith, Castaneda, Alejandro R, Sweeney, Colleen A, Vogel, Christoph F A. 2023. Regulation of IDO2 by the Aryl Hydrocarbon Receptor (AhR) in Breast Cancer. In Cells, 12, . doi:10.3390/cells12101433. https://pubmed.ncbi.nlm.nih.gov/37408267/
5. Li, Pengcheng, Xu, Weiqi, Liu, Furong, Liang, Huifang, Song, Jia. 2021. The emerging roles of IDO2 in cancer and its potential as a therapeutic target. In Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 137, 111295. doi:10.1016/j.biopha.2021.111295. https://pubmed.ncbi.nlm.nih.gov/33550042/
6. Suvieri, Chiara, Belladonna, Maria Laura, Volpi, Claudia. 2024. The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2). In Cells, 13, . doi:10.3390/cells13221894. https://pubmed.ncbi.nlm.nih.gov/39594642/
智鼠故事 
